# Theseus Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/theseus-pharmaceuticals

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.theseusrx.com
- Total disclosed funding: $95M
- Latest round: Series B (Jan 22, 2021)
- Investors on record: 11

## About

Based in New York, US, and founded in 2017, Theseus Pharmaceuticals, Inc., is a biotechnology company designed to develop pan-variant kinase inhibitors. Victor Rivera, David Dalgarno, Wei-Sheng Huang, and William Shakesphere are the co-founders, and Tim Clackson is the President and CEO of the company as of 2021. In April 2021, Theseus Pharmaceuticals, Inc. raised USD 100 million in series B funding from investors including Foresite Capital, Adage Capital Management, Boxer Capital, Farallon Capital Management, Longitude Capital, and more. In October 2021, the firm became a publicly listed company on the Nasdaq under the ticker symbol THRX. In December 2023, Theseus Pharmaceuticals, Inc., a portfolio company of Adage Capital Management, Farallon Capital Management, Foresite Capital, OrbiMed Advisors, Nextech, Omega Funds, Pontifax Venture Capital, Rock Springs Capital and T Rowe Price  agreed to merge into Concentra, Inc., a portfolio company of Cressey & Company, Welsh, Carson, Anderson & Stowe, Select Medical Corporation. The company focuses on the research and development of medicines designed to predict and block treatment-resistant cancer mutations, as well as the treatment of refractory GIST, helping the healthcare industry to address cancer resistance concerns. THE-630, a next-generation pan-variant KIT inhibitor under research by Theseus Pharmaceuticals for the treatment of refractory GIST, is a next-generation pan-variant KIT inhibitor in development. Theseus' pipeline also provides a targeted EGFR inhibitor to treat patients with non-small cell lung cancer who have C797S-mediated resistance to osimertinib in the first or second line. Theseus is developing tyrosine kinase inhibitors (TKIs) for targeted therapies that address all major drug resistance mutations and a fourth-generation, selective epidermal growth factor receptor (EGFR) inhibitor for C797S-mediated resistance to first- or second-line osimertinib treatment in patients with non-small cell lung cancer (NSCLC).

## Funding rounds

- Series B, Jan 22, 2021, $95M — OrbiMed Advisors, T Rowe Price, Adage Capital Management, Longitude Capital, Nextech, Pontifax Venture Capital, Omega Funds, Foresite Capital, Rock Springs Capital, Farallon Capital Management, Boxer Capital

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series B
- T Rowe Price (https://capitalatlas.ai/funds/t-rowe-price) — Series B
- Adage Capital Management — Series B
- Longitude Capital (https://capitalatlas.ai/funds/longitude-capital) — Series B
- Nextech (https://capitalatlas.ai/funds/nextech) — Series B
- Pontifax Venture Capital (https://capitalatlas.ai/funds/pontifax-venture-capital) — Series B
- Omega Funds (https://capitalatlas.ai/funds/omega-funds) — Series B
- Foresite Capital (https://capitalatlas.ai/funds/foresite-capital) — Series B
- Rock Springs Capital — Series B
- Farallon Capital Management (https://capitalatlas.ai/funds/farallon-capital-management) — Series B
- Boxer Capital (https://capitalatlas.ai/funds/boxer-capital) — Series B